Drug intelligence / Profile preview

qingre lidan

Development stage
Phase 2
Modality
Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
Administration
Oral
01

Overview

Qingre Lidan is a traditional Chinese medicine compound formulation used primarily for hepatobiliary diseases such as cholelithiasis (gallstones), cholecystitis (inflammation of the gallbladder), intrahepatic cholestasis, and jaundice. It is available in several forms including tablets (QLTs), granules, and decoction. The formula typically contains multiple herbal ingredients such as Scutellaria baicalensis root (Huang Qin), Lysimachia christinae herb (Jin Qian Cao), Lonicera japonica flower (Jin Yin Hua), Artemisia capillaris herb top (Yin Chen Hao), Bupleurum chinense root (Chai Hu), Isatis tinctoria leaf (Da Qing Ye), Rheum officinale root/rhizome (Da Huang) among others[5][8][10]. Mechanistically, studies indicate that Qingre Lidan acts by activating the farnesoid X receptor in the liver and intestines to regulate bile acid metabolism and promote bile excretion[6][7]. It upregulates transporter proteins such as bile salt export pump and multidrug resistance-associated protein 2 to enhance hepatic bile excretion[6][7]. The preparation also exhibits anti-inflammatory effects by reducing oxidative stress and inflammatory infiltration in liver tissue. Active components identified include baicalein, wogonin, emodin among others[6]. Clinically it has been shown to reduce recurrence rates of choledocholithiasis after surgery[2], alleviate intrahepatic cholestasis symptoms[6], improve liver function indicators in alcoholic liver injury models[3], regulate lipid metabolism/transport genes via NRF2/KEAP1 pathway activation[3], modulate gut microbiota disorders associated with biliary tract disease recurrence prevention[7], and relieve pain associated with biliary tract diseases.

Brand names
Qingre LidanQingre Lidan TabletsQingre Lidan GranulesQingre Lidan Decoction
Other names
QLTsQRLDD利胆片 (Lidan Pian)Lysimachia & Bupleurum Combo
02

Targets

ABCB11 (Bile salt export pump)FXR (Farnesoid x-activated receptor)ABCC2 (ATP-binding cassette sub-family C member 2)

Beyond the preview

Go deeper on qingre lidan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on qingre lidan.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call